Navigation Links
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Date:11/19/2007

hrough paper in Science magazine (Science. 1999 Sep 10;285). Using RNA interference technology to temporarily inhibit p53 in acute settings such as acute kidney injury, apoptosis is delayed thereby allowing natural repair mechanisms to restore normal DNA and cellular integrity.

About Acute Renal Failure (ARF) / Acute Kidney Injury (AKI)

ARF is a syndrome characterized by a rapid decline of kidney function leading to death in a high percentage of cases. Major cardiac surgery is one of the many causes of ARF. During cardiac bypass surgery, lack of oxygen caused by reduced local blood flow to the kidneys, followed by rapid reintroduction of oxygen, or reperfusion, to the kidneys upon removal of the patient from cardiopulmonary bypass, initiates a chain of events that can lead to ARF. Currently, there are no approved drug therapies that effectively prevent or treat ARF.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company focused on discovering and developing novel therapeutics based on its proprietary gene discovery science and technology, with an initial focus on drug candidates that work through the natural mechanism in the cell known as RNA interference, or RNAi, for the treatment of diseases associated with oxidative stress. Quark believes that its proprietary target gene discovery platform, BiFARTM, combined with its ability to design and successfully deliver synthetic molecules of the new class of RNAi therapeutics known as small-interfering RNA, or siRNA, to specific organs in the body, enables the Company to rapidly develop drug candidates. Quark has two internally discovered and developed clinical stage lead product candidates: RTP801i-14 in phase I/IIa clinical trial for the treatment of wet age-related macular degeneration, and AKIi-5 in phase I for the prevention of acute renal failure both of which have an AtuRNAi technology-based structure licensed from Silence Therapeutics, as
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
(Date:8/29/2014)... 29, 2014   Vittamed Corporation , a neurodiagnostics medical ... today that T. (Teo) Forcht Dagi , MD, DmedSc, ... of Directors. " Teo Forcht Dagi ... medical innovation and venture capital," said Remis Bistras , ... add his clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Designs, a company specializing in fashionable medical ID bracelets ... available in an additional 1,100 pharmacies by the end of ... products to more than 1,800. The company ... offering stylish key chains, necklaces, flash drives and bracelets available ...
... 2011 A new prostate cancer study ... surgical treatment to "watchful waiting" revealed important findings ... currently debating their treatment options. (Photo:   ... offered clinical options for early prostate cancer treatment ...
Cached Medicine Technology:Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 2Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 3
(Date:9/1/2014)... The National Association of Hispanic Nurses ( ... DNP, MPH, RN, and Adriana Perez, PhD, Rn, ANP-BC, ... Nursing. They will be inducted with Immediate Past President ... we reported last May. , Our three members will ... American Academy of Nursing Policy Conference in Washington, DC. ...
(Date:9/1/2014)... 2014 Bioinformatics refers to an ... biological and genetic data. A major part of ... software tools to generate and process useful biological ... biological computation. While bioinformatics simply makes use of ... its related concepts, biological computation refers to the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many web hosting ... Top10BestSEOHosting.com is here to announce that JustHost, Bluehost ... in 2014. , JustHost ( http://www.justhost.com/track/seohosts ) provides ... hosting plan. The company’s approach to hosting is ... accessible and powerful enough for anyone to use. ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... Dec. 19 House Republican Whip,Roy Blunt (Mo.) issued ... funding under the State Children,s Health Insurance,Program (SCHIP) through ... days of the first session of the 110th,Congress, the ... for months - a proposal to extend the current ...
... IDEXX Laboratories,Inc. (Nasdaq: IDXX ), announced today ... Conference. Jonathan W. Ayers, Chairman,President and CEO, is scheduled ... 7, 2008 at 8:00 a.m. (PT), at the Westin ... live audio webcast of,the presentation through a link on ...
... Stronger National,Measures, Urges America,s Health Insurance Plan Proposal ... The National Patient,Advocate Foundation (NPAF) -- a national, ... to health care through state and,federal public policy ... today in its Individual Market Guarantee Access,Proposal that ...
... introduce NutreStore(TM) in spring 2008, TORRANCE, ... a,Torrance, California based pharmaceutical company, announced today ... agreement with Cato BioVentures of,Research Triangle Park, ... brand L-Glutamine. Under this agreement, Emmaus will,commercialize ...
... happiness and sadness. Although lost opportunities and mistaken expectations ... experiences may impact personality development and overall happiness. A ... the University of Missouri, indicates that individuals who take ... more likely to mature and achieve a potentially more ...
... in tumor-suppressing gene could point to lymph node involvement, ... Supposedly "innocent" cells in the area surrounding cancerous tumors ... can predict whether or not the cancer spreads to ... of alterations in the tumor-suppressing p53 gene in the ...
Cached Medicine News:Health News:Leading National Patient Advocacy Group Commends Insurance Industry's Recognition, Focus on Growing National Problem of Uninsured and Underinsured Americans 2Health News:Leading National Patient Advocacy Group Commends Insurance Industry's Recognition, Focus on Growing National Problem of Uninsured and Underinsured Americans 3Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 2Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 3Health News:What's the rush? Taking time to acknowledge loss is not that bad 2Health News:Area Around Breast Tumor May Predict Cancer's Spread 2Health News:Area Around Breast Tumor May Predict Cancer's Spread 3
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
Medicine Products: